Evidence map›Paper›PMID 35788726›Full record

ArticleJournal of cancer research and clinical oncology2023

Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors.

George Mellgard, Vaibhav G Patel, Xiaobo Zhong, Himanshu Joshi, Qian Qin, Bo Wang, Anish Parikh, Tomi Jun, Parissa Alerasool, Philip Garcia and 6 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Neuro-immune cross-talk in cancer.Nature reviews. Cancer · 2025
    Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Observational
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

George Mellgard *Division of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, Box 1128, New York, NY, 10029, USA.
Vaibhav G Patel *Division of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, Box 1128, New York, NY, 10029, USA. vaibhav.patel@mountsinai.org.
Xiaobo ZhongDepartment of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, USA.
Himanshu JoshiDepartment of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, USA.
Qian QinDivision of Hematology and Medical Oncology, Department of Medicine, University of Texas Southwestern, Dallas, USA.
Bo WangDivision of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, Box 1128, New York, NY, 10029, USA.
Anish ParikhDivision of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, Box 1128, New York, NY, 10029, USA.
Tomi JunSema4, Stamford, CT, USA.
Parissa AlerasoolSchool of Medicine, New York Medical College, Valhalla, NY, USA.
Philip GarciaDivision of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, Box 1128, New York, NY, 10029, USA.
Mahalya Gogerly-MoragodaDivision of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, Box 1128, New York, NY, 10029, USA.
Amanda LeiterDivision of Endocrinology, Diabetes and Bone Disease, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, USA.
Emily J GallagherDivision of Endocrinology, Diabetes and Bone Disease, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, USA.
William K OhDivision of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, Box 1128, New York, NY, 10029, USA.
Matthew D GalskyDivision of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, Box 1128, New York, NY, 10029, USA.
Che-Kai TsaoDivision of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, Box 1128, New York, NY, 10029, USA.
Icahn School of Medicine at Mount Sinai · USNew York Medical College · USSema4 (United States) · USThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · USThe University of Texas Southwestern Medical Center · US

Funding

Conduits: Mount Sinai Health System Translational Science HubUL1TR004419 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Rosalind J Wright · 2022 to 2026
$46.4M
Training Program in Cancer Prevention and Control for Priority PopulationsT32CA225617 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Guy H Montgomery, JUAN P WISNIVESKY · 2018 to 2026
$2.6M
NCATS NIH HHS UL1 TR004419NCI NIH HHS T32 CA225617
6 · The paper itself

Abstract

purposeStress-induced adrenergic signaling can suppress the immune system. In animal models, pharmacological beta-blockade stimulates CD8 + T-cell activity and improves clinical activity of immune checkpoint blockade (ICB) in inhibiting tumor growth. Herein, we investigated the effect of BB on clinical outcomes of patients receiving ICB in advanced solid tumors.

methodsWe retrospectively evaluated patients with solid tumors treated with ICB at our institution from January 1, 2011 to April 28, 2017. The primary clinical outcome was disease control. Secondary clinical outcomes were overall survival (OS), and duration of therapy (DoT). The primary predictor was use of BB. Association between disease control status and BB use was assessed in univariable and multivariable logistic regression. OS was calculated using hazard ratios of BB-recipient patients vs. BB non-recipient patients via Cox proportional hazards regression models. All tests were two-sided at a significance level of 0.05.

resultsOf 339 identified patients receiving ICB, 109 (32%) also received BB. In covariate-adjusted analysis, odds of disease control were significantly higher among BB recipients compared to BB-non-recipients (2.79; [1.54-5.03]; P = 0.001). While we did not observe significant association of OS with the use of BB overall, significant association with better OS was observed for the urothelial carcinoma cohort (HR: 0.24; [0.09, 0.62]; P = 0.0031).

conclusionsConcurrent use of BB may enhance the clinical activity of ICB and influence overall survival, particularly in patients with urothelial carcinoma. Our findings warrant further investigation to understand the interaction of beta adrenergic signaling and antitumor immune activity and explore a combination strategy.

Indexed as

Carcinoma, Transitional CellUrinary Bladder NeoplasmsHumansImmune Checkpoint InhibitorsProportional Hazards ModelsRetrospective StudiesImmune Checkpoint InhibitorsAdrenergic beta-antagonistsImmunotherapyNeoplasm

Identifiers

PMID35788726
PMCPMC10739778
OpenAlexW4283811790

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.